French companies tap into precision medicine project

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Benedetta Barbanti / EyeEm)
(Image: Getty/Benedetta Barbanti / EyeEm)

Related tags: Precision medicine, Project management, Preclinical services, Clinical development

Medicen Paris Region and Cap Digital announced are encouraging their members to support Hu-PreciMED, a precision medicine project launched by Oncodesign, Servier, and Intersystems.

Human Precision MEDicine (Hu-PreciMED) was created in an aim to structure the precision medicine industry in France. The project includes more than 45 digital and medical companies, and has a goal to bring together all public and private industry members and connect them to medical data from patients. 

Precision medicine uses analysis of molecular and genetic characteristics to develop individualized or personalized treatment and monitoring. According to a press release, the industry is predicted to reach $96bn by 2024.

By connecting these companies with data, the project aims to improve the therapeutic and diagnostic tools currently available.

The project has three main areas each led by a specific coordinator. The components include: Target resolution led by Interesystems; investigation of new molecules by Servier; and preclinical and clinical development lead by Oncodesign.

The project will run in four phases, with the fourth expected to be complete in 2024.

The focus of the pilot program will be on immune-inflammatory diseases that affect 5-7% of the Western population with the goal of identifying the most relevant targets.

Two digital platforms will be used to manage the three components of the project, one for data integration and the other for data analysis.

Medicen Paris Region and Cap Digital are important players in the push advance the Hu-PreciMED project, as together the organizations have more than 1,400 members, and serve as competiveness clusters​.

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars